Short Interest in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Grows By 95.9%

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 65,485 shares, an increase of 95.9% from the May 31st total of 33,421 shares. Based on an average daily trading volume, of 64,658 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Nanobiotix

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new position in Nanobiotix in the 4th quarter worth approximately $390,000. Marshall Wace LLP acquired a new stake in Nanobiotix during the 4th quarter valued at approximately $220,000. Finally, Royal Bank of Canada lifted its stake in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares during the period. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Price Performance

Shares of NBTX traded up $1.76 during trading hours on Wednesday, reaching $39.46. 63,774 shares of the company traded hands, compared to its average volume of 62,758. The business has a fifty day moving average price of $38.67 and a 200-day moving average price of $30.72. Nanobiotix has a 12-month low of $4.73 and a 12-month high of $57.14.

Nanobiotix (NASDAQ:NBTX) last issued its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The business had revenue of $3.42 million during the quarter. On average, equities research analysts predict that Nanobiotix will post 0.19 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NBTX. Leerink Partners upped their target price on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. UBS Group boosted their price target on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. TD Cowen restated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.33.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.